Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium

Paul E. Drawz; Malini Desilva; Peter Bodurtha; Gabriela Vazquez Benitez; Anne M Murray; Alanna M. Chamberlain; R. Adams Dudley; Stephen Waring; Anupam B. Kharbanda; Daniel Murphy; Miriam Halstead Muscoplat; Victor Melendez; Karen L. Margolis; Lynn Mcfarling; Roxana Lupu; Tyler N.A. Winkelman; Steven G. Johnson

doi:10.1093/cid/ciac110

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium

Paul E. Drawz, Malini Desilva, Peter Bodurtha, Gabriela Vazquez Benitez, Anne M Murray, Alanna M. Chamberlain, R. Adams Dudley, Stephen Waring, Anupam B. Kharbanda, Daniel Murphy, Miriam Halstead Muscoplat, Victor Melendez, Karen L. Margolis, Lynn Mcfarling, Roxana Lupu, Tyler N.A. Winkelman, Steven G. Johnson

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Using vaccine data combined with electronic health records, we report that mRNA boosters provide greater protection than a 2-dose regimen against SARS-CoV-2 infection and related hospitalizations. The benefit of a booster was more evident in the elderly and those with comorbidities.

Original language	English (US)
Pages (from-to)	890-892
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	75
Issue number	5
DOIs	https://doi.org/10.1093/cid/ciac110
State	Published - Sep 1 2022

Bibliographical note

Funding Information:
Potential conflicts of interest. A. B. K. and M. D. report funding from the Centers for Disease Control and Prevention (VISION grant, subcontract from HealthPartners Research Institute). V. M. reports funding from Janssen Pharmaceuticals for participation in the COVID-19 vaccine ENSEMBLE clinical trial. R. A. D. reports funding from the US Department of Veterans Affairs, the Agency for Healthcare Research and Quality, and the National Heart, Lung, and Blood Institute and an unpaid leadership or fiduciary role for the National Academy of Medicine, Minneapolis Veterans Affairs Medical Center, and Hennepin County Medical Center. S. W. reports being member and past chair of the governing board for the Health Care Systems Research Network, member of the board of directors for the American College of Epidemiology, member of the board for the Epidemiology Foundation, and member of the Advisory Council in Aging (Area Agency on Aging). All other authors report no potential conflicts of interest.

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.

Keywords

COVID-19
SARS-CoV-2
booster
hospitalization
vaccine

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1093/cid/ciac110

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium'. Together they form a unique fingerprint.

Cite this

Drawz, P. E., Desilva, M., Bodurtha, P., Vazquez Benitez, G., Murray, A. M., Chamberlain, A. M., Dudley, R. A., Waring, S., Kharbanda, A. B., Murphy, D., Muscoplat, M. H., Melendez, V., Margolis, K. L., Mcfarling, L., Lupu, R., Winkelman, T. N. A., & Johnson, S. G. (2022). Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium. Clinical Infectious Diseases, 75(5), 890-892. https://doi.org/10.1093/cid/ciac110

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium. / Drawz, Paul E.; Desilva, Malini; Bodurtha, Peter et al.
In: Clinical Infectious Diseases, Vol. 75, No. 5, 01.09.2022, p. 890-892.

Research output: Contribution to journal › Article › peer-review

Drawz, PE, Desilva, M, Bodurtha, P, Vazquez Benitez, G, Murray, AM, Chamberlain, AM, Dudley, RA, Waring, S, Kharbanda, AB, Murphy, D, Muscoplat, MH, Melendez, V, Margolis, KL, Mcfarling, L, Lupu, R, Winkelman, TNA & Johnson, SG 2022, 'Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium', Clinical Infectious Diseases, vol. 75, no. 5, pp. 890-892. https://doi.org/10.1093/cid/ciac110

Drawz PE, Desilva M, Bodurtha P, Vazquez Benitez G, Murray AM, Chamberlain AM et al. Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium. Clinical Infectious Diseases. 2022 Sep 1;75(5):890-892. doi: 10.1093/cid/ciac110

Drawz, Paul E. ; Desilva, Malini ; Bodurtha, Peter et al. / Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations : A Statewide Report From the Minnesota Electronic Health Record Consortium. In: Clinical Infectious Diseases. 2022 ; Vol. 75, No. 5. pp. 890-892.

@article{6a7e1597df6c4596919b420d6b7e413b,

title = "Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium",

abstract = "Using vaccine data combined with electronic health records, we report that mRNA boosters provide greater protection than a 2-dose regimen against SARS-CoV-2 infection and related hospitalizations. The benefit of a booster was more evident in the elderly and those with comorbidities.",

keywords = "COVID-19, SARS-CoV-2, booster, hospitalization, vaccine",

author = "Drawz, {Paul E.} and Malini Desilva and Peter Bodurtha and {Vazquez Benitez}, Gabriela and Murray, {Anne M} and Chamberlain, {Alanna M.} and Dudley, {R. Adams} and Stephen Waring and Kharbanda, {Anupam B.} and Daniel Murphy and Muscoplat, {Miriam Halstead} and Victor Melendez and Margolis, {Karen L.} and Lynn Mcfarling and Roxana Lupu and Winkelman, {Tyler N.A.} and Johnson, {Steven G.}",

note = "Funding Information: Potential conflicts of interest. A. B. K. and M. D. report funding from the Centers for Disease Control and Prevention (VISION grant, subcontract from HealthPartners Research Institute). V. M. reports funding from Janssen Pharmaceuticals for participation in the COVID-19 vaccine ENSEMBLE clinical trial. R. A. D. reports funding from the US Department of Veterans Affairs, the Agency for Healthcare Research and Quality, and the National Heart, Lung, and Blood Institute and an unpaid leadership or fiduciary role for the National Academy of Medicine, Minneapolis Veterans Affairs Medical Center, and Hennepin County Medical Center. S. W. reports being member and past chair of the governing board for the Health Care Systems Research Network, member of the board of directors for the American College of Epidemiology, member of the board for the Epidemiology Foundation, and member of the Advisory Council in Aging (Area Agency on Aging). All other authors report no potential conflicts of interest. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/cid/ciac110",

language = "English (US)",

volume = "75",

pages = "890--892",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations

T2 - A Statewide Report From the Minnesota Electronic Health Record Consortium

AU - Drawz, Paul E.

AU - Desilva, Malini

AU - Bodurtha, Peter

AU - Vazquez Benitez, Gabriela

AU - Murray, Anne M

AU - Chamberlain, Alanna M.

AU - Dudley, R. Adams

AU - Waring, Stephen

AU - Kharbanda, Anupam B.

AU - Murphy, Daniel

AU - Muscoplat, Miriam Halstead

AU - Melendez, Victor

AU - Margolis, Karen L.

AU - Mcfarling, Lynn

AU - Lupu, Roxana

AU - Winkelman, Tyler N.A.

AU - Johnson, Steven G.

N1 - Funding Information: Potential conflicts of interest. A. B. K. and M. D. report funding from the Centers for Disease Control and Prevention (VISION grant, subcontract from HealthPartners Research Institute). V. M. reports funding from Janssen Pharmaceuticals for participation in the COVID-19 vaccine ENSEMBLE clinical trial. R. A. D. reports funding from the US Department of Veterans Affairs, the Agency for Healthcare Research and Quality, and the National Heart, Lung, and Blood Institute and an unpaid leadership or fiduciary role for the National Academy of Medicine, Minneapolis Veterans Affairs Medical Center, and Hennepin County Medical Center. S. W. reports being member and past chair of the governing board for the Health Care Systems Research Network, member of the board of directors for the American College of Epidemiology, member of the board for the Epidemiology Foundation, and member of the Advisory Council in Aging (Area Agency on Aging). All other authors report no potential conflicts of interest. Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Using vaccine data combined with electronic health records, we report that mRNA boosters provide greater protection than a 2-dose regimen against SARS-CoV-2 infection and related hospitalizations. The benefit of a booster was more evident in the elderly and those with comorbidities.

AB - Using vaccine data combined with electronic health records, we report that mRNA boosters provide greater protection than a 2-dose regimen against SARS-CoV-2 infection and related hospitalizations. The benefit of a booster was more evident in the elderly and those with comorbidities.

KW - COVID-19

KW - SARS-CoV-2

KW - booster

KW - hospitalization

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85138446902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138446902&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac110

DO - 10.1093/cid/ciac110

M3 - Article

C2 - 35137021

AN - SCOPUS:85138446902

SN - 1058-4838

VL - 75

SP - 890

EP - 892

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this